Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer

M. Z. Berger, M. G. Kris, R. J. Gralla, L. D. Marks, L. M. Potanovich, J. J. Dimaggio, R. T. Heelan

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Amonafide (benzisoquinolinedione, nafidimide, NSC 308847) is an anticancer agent that functions as a DNA intercalator. Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. No major objective responses were observed among the 14 patients adequately treated (95% confidence limits 0-20%). Local reactions at the injection site or phlebitis were seen in 14 of the 16 patients. Leukopenia (44%), nausea or vomiting (38%), and thrombocytopenia and rash (each 25%) were also noted. With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer.

Original languageEnglish (US)
Pages (from-to)124-126
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number2
DOIs
StatePublished - Jan 1 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Berger, M. Z., Kris, M. G., Gralla, R. J., Marks, L. D., Potanovich, L. M., Dimaggio, J. J., & Heelan, R. T. (1991). Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 14(2), 124-126. https://doi.org/10.1097/00000421-199104000-00006